Humira grew 7% in the US last year, mainly due to price increases, but the product felt the effects of biosimilar competition in the smaller European market, where sales operationally fell 23% ...

This era was marked by the approval of Johnson & Johnson’s (J&J) Remicade (infliximab) in 2005 for ulcerative colitis (UC) in the US, followed by AbbVie’s Humira (adalimumab) in 2012 and J&J ...